Here we show that in a mouse model of endotoxemia induced by LPS administration, preventive or curative therapeutic approaches using a monoclonal antibody directed against PCSK9 at doses more than 10× higher than those used in humans did not reduce LPS-induced death (Figs. 1, 3, 5). Here, PCSK9 is linked to serum lipopolysaccharide activity.